$17.94
2.40% yesterday
Nasdaq, Apr 02, 10:00 pm CET
ISIN
JE00BYSS4X48
Symbol
NVCR

Novocure Ltd. Stock price

$17.94
-0.47 2.55% 1M
+2.44 15.74% 6M
-11.86 39.80% YTD
+3.55 24.67% 1Y
-71.96 80.04% 3Y
-48.34 72.93% 5Y
-0.34 1.86% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.42 2.40%
ISIN
JE00BYSS4X48
Symbol
NVCR
Sector

Key metrics

Market capitalization $1.97b
Enterprise Value $1.69b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.80
P/S ratio (TTM) P/S ratio 3.26
P/B ratio (TTM) P/B ratio 5.41
Revenue growth (TTM) Revenue growth 18.82%
Revenue (TTM) Revenue $605.22m
EBIT (operating result TTM) EBIT $-167.54m
Free Cash Flow (TTM) Free Cash Flow $-69.22m
Cash position $962.20m
EPS (TTM) EPS $-1.56
P/E forward negative
P/S forward 3.21
EV/Sales forward 2.76
Short interest 5.85%
Show more

Is Novocure Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Novocure Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Novocure Ltd. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Novocure Ltd. forecast:

Buy
83%
Hold
17%

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
605 605
19% 19%
100%
- Direct Costs 136 136
7% 7%
23%
469 469
23% 23%
78%
- Selling and Administrative Expenses 416 416
11% 11%
69%
- Research and Development Expense 209 209
5% 5%
35%
-156 -156
27% 27%
-26%
- Depreciation and Amortization 11 11
2% 2%
2%
EBIT (Operating Income) EBIT -168 -168
26% 26%
-28%
Net Profit -169 -169
19% 19%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Novocure Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novocure Ltd. Stock News

Neutral
Business Wire
2 days ago
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company's financial results for the three-month quarter that ended March 31, 2025. To access the conference call by ph...
Positive
The Motley Fool
29 days ago
Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
Business Wire
30 days ago
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be a...
More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office Jersey
CEO Ashley Cordova
Employees 1,488
Founded 2000
Website www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today